Skip to main
COR

Cencora Inc (COR) Stock Forecast & Price Target

Cencora Inc (COR) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 54%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Cencora is in a strong position in the pharmaceutical wholesale industry, with a dominant market share alongside McKesson and Cardinal Health. The company's expansion into international markets through the acquisition of Alliance Healthcare in Europe provides additional growth opportunities. Despite potential regulatory challenges to drug pricing and reimbursement, its strategy to focus on specialty pharmaceuticals and vertical integration into higher-margin services should aid in navigating these headwinds.

Bears say

Cencora is primarily focused on pharmaceutical distribution to healthcare providers and lacks diversification in its growth drivers. With potential antitrust concerns and increased regulatory scrutiny on distribution economics, the company's market share and profitability may be at risk. Furthermore, customer concentration and contract renewal risks, as well as cybersecurity threats, could impact the company's revenue visibility and reputation. This negative outlook is reflected in our price target of $330 and Sector Perform rating, as we believe Cencora will face challenges in maintaining its current market share and profitability in the competitive pharmaceutical distribution industry.

Cencora Inc (COR) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 54% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cencora Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cencora Inc (COR) Forecast

Analysts have given Cencora Inc (COR) a Buy based on their latest research and market trends.

According to 13 analysts, Cencora Inc (COR) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $368.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $368.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cencora Inc (COR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.